AtaiBeckley (ATAI) is exploring a potential sale or partnership for BPL-003, a psychedelic drug candidate for severe depression, seeking to fetch at least $2 billion from a deal, Bloomberg reported Saturday, citing people familiar with the matter.

The company could sign a co-commercialization deal, under which AtaiBeckley would share obligations, including stage 3 trial expenses and marketing for BPL-003, while splitting revenues and profits with a partner, Bloomberg said, citing the people.

AtaiBeckley could also work out a royalty deal, the people reportedly said, adding that the company aims to conclude talks in Q2.

Talks are ongoing, and no final decisions have been made, the people added, according to the report.

AtaiBeckley did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 3.73, Change: +0.34, Percent Change: +9.88